4.90
-0.2(-3.92%)
Currency In USD
| Previous Close | 5.1 |
| Open | 5.05 |
| Day High | 5.09 |
| Day Low | 4.86 |
| 52-Week High | 7.18 |
| 52-Week Low | 1.29 |
| Volume | 1.74M |
| Average Volume | 2.88M |
| Market Cap | 586.02M |
| PE | -3.48 |
| EPS | -1.41 |
| Moving Average 50 Days | 5.52 |
| Moving Average 200 Days | 3.36 |
| Change | -0.2 |
If you invested $1000 in Annexon, Inc. (ANNX) since IPO date, it would be worth $275.9 as of February 21, 2026 at a share price of $4.9. Whereas If you bought $1000 worth of Annexon, Inc. (ANNX) shares 5 years ago, it would be worth $148.31 as of February 21, 2026 at a share price of $4.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million peopl
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANN